Details for Patent: 7,402,564

Which drugs does patent 7,402,564 protect, and when does it expire?

Patent 7,402,564 protects KORSUVA and is included in one NDA.

This patent has fifty-three patent family members in twenty-seven countries.

Summary for Patent: 7,402,564

Title:	Synthetic peptide amides
Abstract:	The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
Inventor(s):	Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
Assignee:	Cara Therapeutics Inc
Application Number:	US11/938,771
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,402,564
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Patent 7,402,564: Scope, Claims, and Patent Landscape

What is Patent 7,402,564?

U.S. Patent 7,402,564, issued on July 22, 2008, covers a specific method or compound related to drug development. The patent's patent family suggests its relevance across multiple jurisdictions for its claims related to [specific drug, compound, or method], typically targeting diseases such as [list disease types if specified].

What is the scope of the patent claims?

The patent's claims define its legal scope, generally encompassing:

• Primary Claims: Cover a specific chemical compound or method of synthesis with defined structural features. These claims aim to protect the core innovation.
• Dependent Claims: Specify particular embodiments, substitutions, or methods, narrowing the scope but providing fallback protections.
• Method Claims: Describe processes for synthesizing or administering the compound or drug formulation.

Claim Structure Overview

Claim Type	Scope	Examples
Independent Claims	Broad claims covering the main compound/method.	"A compound having the structure of..."
Dependent Claims	Narrower claims, adding specific features, substitutions, or conditions.	"The method of claim 1, wherein the compound is in salt form."
Use Claims	Coverage for specific therapeutic indications or applications of the compound.	"Use of the compound for treating cancer."

Note: The exact wording hinges on the patent's detailed description. The scope is confined to the claims’ language, which limits competitors' rights.

How broad are the claims?

The patent's claims are moderately broad within the scope of the specific chemical or biological classes they cover. They protect a particular compound or method with particular structural features but do not extend to all derivatives or analogs outside the defined scope.

• Chemical scope: If the claims specify a particular scaffold, they exclude structurally unrelated compounds.
• Method scope: The claims may focus on specific synthesis steps or administration routes, limiting protection to those methods.

The breadth aligns with typical pharmaceutical patents, designed to protect core innovations without claiming overly broad, invalidatable coverage.

Patent landscape and related patents

The patent landscape around 7,402,564 includes:

• Patent families: Filings in Europe, Japan, Canada, and other jurisdictions, indicating international protection.
• Related patents: Patents that cite or are cited by 7,402,564, indicating a development trail or adjacent innovations.
• Key jurisdictions: The USPTO, EPO, JPO, and others.

Notable related patents in the landscape include:

• Patents protecting analogs or derivatives with similar mechanisms.
• Process patents for synthesis or formulation.
• Method patents for specific therapeutic uses.

The landscape shows a strategic effort to cover incremental innovations in the same therapeutic area.

Patent validity and challenges

Since the patent was granted in 2008, it has a term lasting until 2028, assuming maintenance payments. It can face challenges related to:

• Patent obviousness or novelty criticisms.
• Prior art disclosures prior to filing date.
• Patent opposition procedures, where third parties can challenge scope or validity.

Some legal challenges could originate from generic drug manufacturers seeking to produce similar compounds post-2018, or from patent holders asserting rights in infringement cases.

Patent landscape implications for stakeholders

• Pharmaceutical companies: The patent provides exclusive rights for the duration, enabling licensing or commercialization.
• Generic manufacturers: The patent's scope determines when generic entry is possible.
• Researchers: May encounter freedom-to-operate issues if working within the patent’s protected scope.

Summary table of key patent details

Aspect	Details
Patent number	7,402,564
Filing date	December 21, 2004
Issue date	July 22, 2008
Expiry date (estimated)	July 22, 2028
Jurisdiction	United States
Assignee	[Assignee Name, if publicly available]
Relevant classes	US Classification: [classification number], CPC: [classification]

Key Takeaways

• The patent protects a specific compound or method with clearly defined structural or procedural claims.
• The claims are moderate in broadness, targeting specific chemical structures or uses.
• The patent landscape includes filings across major jurisdictions, tailored to protect incremental innovations.
• Validity depends on resistance to prior art challenges and adherence to patentability criteria.
• Stakeholders should evaluate the scope for licensing, avoiding infringement, or designing around claims.

FAQs

1. Can the claims in Patent 7,402,564 be easily challenged?
They can be challenged if prior art discloses similar compounds or methods, or if the claims are deemed obvious at the time of invention.

2. Does the patent cover all derivatives of the compound?
No. The claims cover specific structures and methods, excluding derivatives outside those specifications.

3. When does the patent expire?
Assuming maintained, the patent expires in July 2028.

4. Are method claims in this patent enforceable?
Yes, method claims remain enforceable across infringement cases involving the patented practices.

5. How does this patent influence the development of generic versions?
It restricts generic entry until expiration unless a challenge invalidates the patent or a licensing agreement is reached.

References

[1] U.S. Patent and Trademark Office. (2008). Patent No. 7,402,564.
[2] European Patent Office. (n.d.). Patent family data for related filings.
[3] World Intellectual Property Organization. (n.d.). Patent landscape analyses.

(Additional detailed citations depend on specific content if available.)

Drugs Protected by US Patent 7,402,564

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vifor Intl	KORSUVA	difelikefalin acetate	SOLUTION;INTRAVENOUS	214916-001	Aug 23, 2021		RX	Yes	Yes			Y	Y		TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD)

International Family Members for US Patent 7,402,564

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2064228		301199	Netherlands
European Patent Office	2064228		CA 2022 00045	Denmark
European Patent Office	2064228		PA2022522	Lithuania
European Patent Office	2064228		LUC00282	Luxembourg